Molnupiravir (Lagevrio®) is an orally-administered antiviral prodrug that inhibits replication
of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback …

Broad‐spectrum antiviral agents targeting viral RNA‐dependent RNA polymerase (RdRp)
are expected to be a key therapeutic strategy in the ongoing coronavirus disease 2019 …

The precocity and efficacy of the vaccines developed so far against COVID-19 has been the
most significant and saving advance against the pandemic. The development of vaccines …

Abstract Treatment of SARS-CoV-2 targeting its RNA dependent RNA polymerase (RdRp) is
of current interest. Remdesivir has been approved for the treatment of COVID-19 around the …

The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
has called for an urgent need for dedicated antiviral therapeutics. Metal complexes are …

This review considers antiviral nucleoside analog (NA) drugs, including ribavirin, favipiravir,
and molnupiravir, which induce genome error catastrophe in SARS‐CoV or SARS‐CoV‐2 …

Coronavirus is a family of viruses that can cause diseases such as the common cold, severe
acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS). The …

An accurate, sensitive and selective RP-HPLC-UV method has been established for the
estimation of Molnupiravir (MOL) in pure bulk powder and pharmaceutical formulation …

Background Throughout the time of the global pandemic of SARS-CoV-2 virus, there has
been a compelling necessity for the development of effective antiviral agents and …

Abstract Molnupiravir (EIDD-2801) is a prodrug of a ribonucleoside analogue that is
currently being used under a US FDA emergency use authorization for the treatment of mild …